NCT05641688 - [18F]PI-2620 Phase 3 Histopathological Study | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

[18F]PI-2620

The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%

Trial Locations (25)

13057

RECRUITING

Velocity Clinical Research, East Syracuse

13219

RECRUITING

Ichor Research, Syracuse

28273

TERMINATED

American Carolina Clinical Research LLC, Charlotte

32159

RECRUITING

K2 Medical Research, Lady Lake

32209

RECRUITING

UF College of Medicine - Jacksonville, Jacksonville

32751

RECRUITING

ClinCloud Research, Maitland

RECRUITING

K2 Medical Research, Maitland

32792

RECRUITING

Charter Research, Winter Park

33016

RECRUITING

Galiz Research, Hialeah

33137

RECRUITING

Miami Jewish Health Systems, Miami

34243

TERMINATED

The Roskamp Institute, Sarasota

44131

RECRUITING

Insight Clinical Trials LLC, Beachwood

45459

RECRUITING

Valley Medical Research, Centerville

68616

RECRUITING

Be Well Clinical Studies, Lincoln

75231

RECRUITING

Baylor Research Institute, Dallas

78028

RECRUITING

Sante Clinical Research, Kerrville

78681

RECRUITING

Be Well Clinical Studies, Round Rock

85013

RECRUITING

Barrow Neurological Institute, Phoenix

85352

RECRUITING

Banner Sun Health Research Institute, Sun City

92562

RECRUITING

Esperanza Clinical, Murrieta

94114

RECRUITING

Sutter Health, San Francisco

90095 - 7370

RECRUITING

UC Los Angeles, Los Angeles

02184

RECRUITING

Alzheimer's Disease Center, Braintree

02360

RECRUITING

Headlands Research, Plymouth

07366

RECRUITING

Darthmouth-Hitchcock Medical Center, Lebanon